	A1 1 1		Add Note
OMB #: 0925-0753	Expiration Date: 07/31/2	021	Add Note
	STATEMENT OF CONFIDENTIALITY		
activities involved with the operations of completion of the forms is voluntary, if y	n — conduct reviews of clinical trial studies. NCI guidelines mandat up studies. You are being requested to complete this instrument so th f the NCI CIRB Initiative. Although your participation in Network grou you wish to participate in the CIRB, you must complete all questions o d for all participants and reported as summaries. It will be kept priva	at we can o p research n the form.	onduct and The
NO	TIFICATION TO RESPONDENT OF ESTIMATED BURDEN		
reviewing instructions, searching existin the collection of information. An agency information unless it displays a current aspect of this collection of information,	on of information is estimated to average 20 minutes per response, i Ing data sources, gathering and maintaining the data needed, and comp (may not conduct or sponsor, and a person is not required to respo y valid OMB control number. Send comments regarding this burden (e including suggestions for reducing this burden, to: NIH, Project Cle ID 20892-7974, ATTN: PRA (0925-0753). Do not return the completed	oleting and nd to, a co estimate or arance Bra	reviewing ellection of any other ench, 6705
Cianatama Institution Information		Add Note	View Audit
Signatory Institution Information 1. Submitting User Information		AUU NOLE	VIEW ADDIC
Name			
Email:	Business Phone:		
(Required) 3. Enter the email address of the Inv	restigator providing this notification	Adc Note	V ew Aucit
(Required)			
1			
4. Signatory Institution (Required)		Add Note	View Audit
CIRE Operations Office •			
	ration Number or another unique anonymous identifier for participant. eet for each participant and study impacted.	Add Note	V ew Aucit
(Required)			
	*		

6. Date study participant enrolled and what study arm (if any).	Add Note	View Audit
(Required)		
	5	
7. Date study participant incarcerated.	Add Note	View Audit
(Required)		
8. How and when the PI was notified of the participant's incarceration.	Add Note	View Audit
(Required)		
	۶	
9. Anticipated length of incarceration	Add Note	View Audit
(Required)		
	8	
10. Type of incarceration	Add Note	View Audit
(Required)		
Full incarceration		
<ul> <li>Home confinement</li> <li>Intermittent sentence (jail on the weekends or intermittent blocks of time)</li> </ul>		
Other		
11. Is remaining in the study while incarcerated in the participant's best interest?	Add Note	View Audit
(Required)		
<ul> <li>Yes</li> <li>No (the subject will be removed from the study)</li> </ul>		
Describe justification:	Add Note	View Audit
(Required)		
	8	
		Minut 111
12. Does the participant's status as a prisoner affect the risks or potential benefits of participation in study?	the Add Note	View Audit
(Required)		
• Yes		
No		

13. Are there risks to the participant if treatment is discontinued because of the participant's incarceration?	Add Note	View Audit
(Required)		
● Yes ● No		
14. Will study visits and/or treatment be potentially missed while incarcerated?	Add Note	View Audit
(Required)		
● Yes ● No		
15. How will study visits and/or treatment be handled/ distributed while the participant is incarcerated?	Add Note	View Audit
(Required)		
A65-		

16. Is there a need for follow-up examination or care of the participant after study participation has ended?	Add Note	View Audit
(Required)		
● Yes ● No		
17. Attach any additional documentation	Add Note	View Audit
Add Attachment		

Next Save for Later More +